Clonazepam in the pharmacological treatment of vertigo and tinnitus

Authors

Dr Flávio Serafini (São Paulo, Brazil)
Dr. Mario Munhoz (Minas Gerais, Brazil)
Prof. Dr. Mauricio Malavasi Ganança (São Paulo, Brazil)
Dr. Heloisa Helena Caovilla (São Paulo, Brazil)
Dr. Fernando Freitas Ganança (São Paulo, Brazil)
Dr. Cristina Freitas Ganança (São Paulo, Brazil)
Dr. Maria Leonor Garcia da Silva (São Paulo, Brazil)

Topics

Neurootology
Equilibrium
Diseases
Sensology
Hearing
Diseases
Neurootology
Equilibrium
Sensology
Hearing
Neurootology
Neurootologic therapy
Neurootology
Neurootology
Neurootologic therapy
Pharmacotherapy
Sensology
Sensology
Hearing
Therapy

Keywords

Clonazepan, Dizziness, Therapy, Tinnitus, Vertigo.

Abstract

We carried out a retrospective survey of 25 years of clinical experience with the use of clonazepam as a vestibular and tinnitus suppressant in the pharmacological treatment of vestibular or cochleovestibular disorders due to different causes.
We reviewed the medical records of 3,357 outpatients treated with a 0.5- or 1.0-mg daily dosage of oral clonazepam during 60 – 180 days. Complete or substantial control of vertigo or nonvertiginous dizziness was achieved in 77.4% of the vertigo patients. Tinnitus was improved in 32.0% of the tinnitus patients. Light or mild drowsiness, depression, nightmares, or lowering of libido, reported by 16.9% of the patients as adverse side effects, tended to subside with continued therapy. We concluded that clonazepam is a very useful and safe drug for the symptomatic treatment of patients suffering from cochleovestibular disorders

International Tinnitus Journal – ITJ, go to http://www.tinnitusjournal.com/